LB Pharmaceuticals Financials - Benzinga

LB Pharmaceuticals Inc

LBRXNASDAQ

Trade with Public

Trade with Public

$47.73

-0.16-0.33%

At close: Aug 28, 5:00 PM EST

$47.73

N/A

After Hours: Aug 28, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

LB Pharmaceuticals Financials

LB Pharmaceuticals (LBRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per

Benzinga Newsdesk

PRO
LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate

LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 95.47 percent increase over losses of $(14.79) per share

Benzinga Newsdesk

PRO
LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share

Benzinga Newsdesk

PRO
LB Pharmaceuticals Q3 EPS $(0.61) Beats $(0.63) Estimate

LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 98.46 percent increase over losses of $(39.49) per share

Benzinga Newsdesk